Abstract: OBJECTIVE To investigate the association between efficacy and safety of atorvastatin and SLCO1B1 gene polymorphisms in hyperlipidemia patients. METHODS The basic information of the patients diagnosed with hyperlipidemia in outpatient clinics of Jinhua People's Hospital in April 2017-April 2018 was collected. The genetic polymorphisms of SLCO1B1 c.388A>G and c.521T>C were included in the patients. Regular follow-up test was conducted, and the related laboratory indexes of triglyceride, cholesterol, low density lipoprotein cholesterol and creatine kinase were measured regularly.RESULTS The frequency distributions of SLCO1B1 c.388A>G and c.521T>C alleles in patients were 72.8% and 15.9%, respectively. At the end of the follow-up period, there was no significant difference in the rate of serum lipid changes among patients with different genotypes. The polymorphisms of SLCO1B1 c.521T>C gene was associated with the safety of atorvastatin(P=0.005).CONCLUSION The polymorphism of SLCO1B1 c.388A>G gene has no effect on the efficacy and safety of atorvastatin in lipid lowering. The polymorphism of SLCO1B1 c.521T>C gene has no correlation with the lipid-lowering effect of atorvastatin, but it has certain influence on its safety.